Acumen Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ABOS$0.23-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(65,175) | $(35,874) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 49 | 42 |
| Stock-based compensation expense | 7,292 | 4,511 |
| Amortization of premiums and accretion of discounts on marketable securities, net | (4,599) | (1,344) |
| Change in fair value of embedded derivatives | (1,040) | — |
| Amortization of right-of-use asset | 85 | 103 |
| Realized gains on marketable securities | (97) | — |
| Non-cash interest expense | 823 | — |
| Other non-cash expense | 230 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4,196) | (436) |
| Other assets | 51 | (38) |
| Accounts payable | 963 | (278) |
| Accrued clinical trial expenses | 8,130 | (1,151) |
| Accrued expenses and other current liabilities | (1,413) | (182) |
| Finance lease liability | (23) | — |
| Operating lease liability | (80) | (103) |
| Net cash used in operating activities | (59,000) | (34,750) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (155,631) | (178,857) |
| Proceeds from maturities and sales of marketable securities | 174,011 | 55,997 |
| Proceeds from sale of property and equipment | — | 3 |
| Purchases of property and equipment | (16) | (7) |
| Net cash provided by (used in) investing activities | 18,364 | (122,864) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of issuance costs | 7,938 | 122,294 |
| Payment for financing lease | (739) | — |
| Payments for deferred offering costs | (230) | — |
| Repurchase of common shares to pay employee withholding taxes | (32) | — |
| Proceeds from exercise of stock options | — | 325 |
| Net cash provided by financing activities | 6,937 | 122,619 |
| Net change in cash and cash equivalents and restricted cash | (33,699) | (34,995) |
| Cash and cash equivalents and restricted cash at the beginning of the period | 67,119 | 130,101 |
| Cash and cash equivalents and restricted cash at the end of the period | $33,420 | $95,106 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for income taxes | $— | $— |
| Cash paid for interest | $2,235 | $— |
| Supplemental disclosure of noncash investing and financing activities | ||
| Proceeds from sale of property and equipment in other current assets | $— | $4 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.